Doctor's opioid prescription conviction tossed after U.S. Supreme Court ruling
Adds comment from defense lawyer in paragraph 4
By Nate Raymond
Feb 3 (Reuters) -A federal appeals court on Friday overturned the conviction of a doctor accused of unlawfully prescribing addictive opioids in Arizona and Wyoming after the U.S. Supreme Court issued a ruling in his favor that made it harder to prosecute such cases.
The Denver-based 10th U.S. Circuit Court of Appeals ruled that under last year's Supreme Court's decision, jurors were wrongly instructed on how to determine whether Shakeel Kahn knowingly prescribed powerful drugs in an illegal manner.
He was at the center of a Supreme Court ruling in January 2022 that raised the bar for what prosecutors must prove to secure convictions of doctors accused of fueling the U.S. opioid crisis by turning their medical practices into "pill mills."
Kahn's lawyer, Beau Brindley, said in a statement Friday's decision "should pave the way to finally ending the practice of unfairly scapegoating doctors for an opiate crisis for which they were never responsible."
Kahn, 56, has been serving a 25-year prison sentence after a jury in Wyoming in 2019 found him guilty of unlawfully distributing prescription medications, operating a continuing criminal enterprise and other charges.
Prosecutors said Kahn from 2011 to 2016 prescribed powerful pain drugs to people in Arizona and Wyoming in exchange for money after performing perfunctory or no examinations. They included one woman who died of an oxycodone overdose.
At trial, Kahn did not contest that patients abused their medications but disputed what his intent was in prescribing them drugs, asserting he had a "good faith" reason to believe his prescriptions were valid.
He took his case to the Supreme Court, which held that prosecutors have to prove that doctors knew they illegally prescribed drugs in violation of the federal Controlled Substances Act.
The justices left to the three-judge 10th Circuit panel to decide whether jurors were properly instructed in Kahn's case under that standard.
U.S. Circuit Judge Mary Beck Briscoe wrote that they were not, saying the instructions "effectively lowered the government’s burden to showing only that Dr. Kahn’s behavior was objectively unauthorized - not that Dr. Kahn intended to act without authorization."
Reporting by Nate Raymond in Boston; Editing by Bill Berkrot
Pinakabagong Balita
Disclaimer: Ang mga kabilang sa XM Group ay nagbibigay lang ng serbisyo sa pagpapatupad at pag-access sa aming Online Trading Facility, kung saan pinapahintulutan nito ang pagtingin at/o paggamit sa nilalaman na makikita sa website o sa pamamagitan nito, at walang layuning palitan o palawigin ito, at hindi din ito papalitan o papalawigin. Ang naturang pag-access at paggamit ay palaging alinsunod sa: (i) Mga Tuntunin at Kundisyon; (ii) Mga Babala sa Risk; at (iii) Kabuuang Disclaimer. Kaya naman ang naturang nilalaman ay ituturing na pangkalahatang impormasyon lamang. Mangyaring isaalang-alang na ang mga nilalaman ng aming Online Trading Facility ay hindi paglikom, o alok, para magsagawa ng anumang transaksyon sa mga pinansyal na market. Ang pag-trade sa alinmang pinansyal na market ay nagtataglay ng mataas na lebel ng risk sa iyong kapital.
Lahat ng materyales na nakalathala sa aming Online Trading Facility ay nakalaan para sa layuning edukasyonal/pang-impormasyon lamang at hindi naglalaman – at hindi dapat ituring bilang naglalaman – ng payo at rekomendasyon na pangpinansyal, tungkol sa buwis sa pag-i-invest, o pang-trade, o tala ng aming presyo sa pag-trade, o alok para sa, o paglikom ng, transaksyon sa alinmang pinansyal na instrument o hindi ginustong pinansyal na promosyon.
Sa anumang nilalaman na galing sa ikatlong partido, pati na ang mga nilalaman na inihanda ng XM, ang mga naturang opinyon, balita, pananaliksik, pag-analisa, presyo, ibang impormasyon o link sa ibang mga site na makikita sa website na ito ay ibibigay tulad ng nandoon, bilang pangkalahatang komentaryo sa market at hindi ito nagtataglay ng payo sa pag-i-invest. Kung ang alinmang nilalaman nito ay itinuring bilang pananaliksik sa pag-i-invest, kailangan mong isaalang-alang at tanggapin na hindi ito inilaan at inihanda alinsunod sa mga legal na pangangailangan na idinisenyo para maisulong ang pagsasarili ng pananaliksik sa pag-i-invest, at dahil dito ituturing ito na komunikasyon sa marketing sa ilalim ng mga kaugnay na batas at regulasyon. Mangyaring siguruhin na nabasa at naintindihan mo ang aming Notipikasyon sa Hindi Independyenteng Pananaliksik sa Pag-i-invest at Babala sa Risk na may kinalaman sa impormasyong nakalagay sa itaas, na maa-access dito.
